BIOMAT Database Logo BIOMAT Database Logo

Virological response to initial antiretroviral regimens containing abacavir or tenofovir. 2009

Loveleen Bansi, and Caroline Sabin, and Richard Gilson, and Brian Gazzard, and Clifford Leen, and Jane Anderson, and David Dunn, and Teresa Hill, and Martin Fisher, and Jonathan Ainsworth, and Deenan Pillay, and Margaret Johnson, and John Walsh, and Chloe Orkin, and Philippa Easterbrook, and Mark Gompels, and Andrew Phillips, and
Research Department of Infection and Population Health, University College Medical School, Royal Free Campus, London, United Kingdom. l.bansi@pcps.ucl.ac.uk

Patients with a baseline viral load >100,000 copies/mL receiving abacavir (ABC) as part of the nucleoside-backbone component of their first highly active antiretroviral therapy (HAART) regimen have been reported to have a greater failure rate than those receiving tenofovir (TDF). We analyzed short-term outcomes of the use of HAART combinations that included ABC or TDF. The mean 2-8-week change in viral load was calculated using linear regression. In total, 1136 patients started ABC, and 412 started TDF. After adjustment for baseline viral load and other factors, there was no difference in the change in viral load between the patients who started ABC and those who started TDF (0.03 [95% confidence interval, -0.07 to 0.12]) log copies/mL; P = .59). Furthermore, there was no evidence that this effect differed according to baseline viral load (P = .88 for the interaction between pre-HAART viral load and nucleoside started). Likewise, there was no difference in rates of virological failure between the 2 drugs at 24-48 weeks after starting HAART.

UI MeSH Term Description Entries
D008297 Male Males
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068698 Tenofovir An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone. (R)-9-(2-phosphonylmethoxypropyl)adenine,9-(2-Phosphonomethoxypropyl)adenine,9-(2-Phosphonylmethoxypropyl)adenine,9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer,9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098,9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer,9-PMPA (tenofovir),Tenofovir Disoproxil,Tenofovir Disoproxil Fumarate,Viread,Disoproxil Fumarate, Tenofovir,Disoproxil, Tenofovir,Fumarate, Tenofovir Disoproxil
D000225 Adenine A purine base and a fundamental unit of ADENINE NUCLEOTIDES. Vitamin B 4,4, Vitamin B,B 4, Vitamin
D015224 Dideoxynucleosides Nucleosides that have two hydroxy groups removed from the sugar moiety. The majority of these compounds have broad-spectrum antiretroviral activity due to their action as antimetabolites. The nucleosides are phosphorylated intracellularly to their 5'-triphosphates and act as chain-terminating inhibitors of viral reverse transcription. 2',3'-Dideoxynucleosides,Dideoxyribonucleosides,ddNus,2',3' Dideoxynucleosides
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017211 Treatment Failure A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series. Failure, Treatment,Failures, Treatment,Treatment Failures

Related Publications

Loveleen Bansi, and Caroline Sabin, and Richard Gilson, and Brian Gazzard, and Clifford Leen, and Jane Anderson, and David Dunn, and Teresa Hill, and Martin Fisher, and Jonathan Ainsworth, and Deenan Pillay, and Margaret Johnson, and John Walsh, and Chloe Orkin, and Philippa Easterbrook, and Mark Gompels, and Andrew Phillips, and
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
October 2009, Infection,
Loveleen Bansi, and Caroline Sabin, and Richard Gilson, and Brian Gazzard, and Clifford Leen, and Jane Anderson, and David Dunn, and Teresa Hill, and Martin Fisher, and Jonathan Ainsworth, and Deenan Pillay, and Margaret Johnson, and John Walsh, and Chloe Orkin, and Philippa Easterbrook, and Mark Gompels, and Andrew Phillips, and
Cardiovascular Events in an Inner-City HIV Clinic and Relationship to Abacavir Versus Tenofovir Disoproxil Fumarate-Containing Antiretroviral Regimens.
January 2021, AIDS research and human retroviruses,
Loveleen Bansi, and Caroline Sabin, and Richard Gilson, and Brian Gazzard, and Clifford Leen, and Jane Anderson, and David Dunn, and Teresa Hill, and Martin Fisher, and Jonathan Ainsworth, and Deenan Pillay, and Margaret Johnson, and John Walsh, and Chloe Orkin, and Philippa Easterbrook, and Mark Gompels, and Andrew Phillips, and
Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.
April 2013, Infection,
Loveleen Bansi, and Caroline Sabin, and Richard Gilson, and Brian Gazzard, and Clifford Leen, and Jane Anderson, and David Dunn, and Teresa Hill, and Martin Fisher, and Jonathan Ainsworth, and Deenan Pillay, and Margaret Johnson, and John Walsh, and Chloe Orkin, and Philippa Easterbrook, and Mark Gompels, and Andrew Phillips, and
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.
December 2001, AIDS (London, England),
Loveleen Bansi, and Caroline Sabin, and Richard Gilson, and Brian Gazzard, and Clifford Leen, and Jane Anderson, and David Dunn, and Teresa Hill, and Martin Fisher, and Jonathan Ainsworth, and Deenan Pillay, and Margaret Johnson, and John Walsh, and Chloe Orkin, and Philippa Easterbrook, and Mark Gompels, and Andrew Phillips, and
Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice?
August 2007, AIDS (London, England),
Loveleen Bansi, and Caroline Sabin, and Richard Gilson, and Brian Gazzard, and Clifford Leen, and Jane Anderson, and David Dunn, and Teresa Hill, and Martin Fisher, and Jonathan Ainsworth, and Deenan Pillay, and Margaret Johnson, and John Walsh, and Chloe Orkin, and Philippa Easterbrook, and Mark Gompels, and Andrew Phillips, and
Initial antiretroviral regimens.
March 2002, BMJ (Clinical research ed.),
Loveleen Bansi, and Caroline Sabin, and Richard Gilson, and Brian Gazzard, and Clifford Leen, and Jane Anderson, and David Dunn, and Teresa Hill, and Martin Fisher, and Jonathan Ainsworth, and Deenan Pillay, and Margaret Johnson, and John Walsh, and Chloe Orkin, and Philippa Easterbrook, and Mark Gompels, and Andrew Phillips, and
Tenofovir-containing nucleoside/nucleotide-only antiretroviral maintenance therapy: decision making and virological outcome.
January 2006, HIV clinical trials,
Loveleen Bansi, and Caroline Sabin, and Richard Gilson, and Brian Gazzard, and Clifford Leen, and Jane Anderson, and David Dunn, and Teresa Hill, and Martin Fisher, and Jonathan Ainsworth, and Deenan Pillay, and Margaret Johnson, and John Walsh, and Chloe Orkin, and Philippa Easterbrook, and Mark Gompels, and Andrew Phillips, and
A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.
March 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Loveleen Bansi, and Caroline Sabin, and Richard Gilson, and Brian Gazzard, and Clifford Leen, and Jane Anderson, and David Dunn, and Teresa Hill, and Martin Fisher, and Jonathan Ainsworth, and Deenan Pillay, and Margaret Johnson, and John Walsh, and Chloe Orkin, and Philippa Easterbrook, and Mark Gompels, and Andrew Phillips, and
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
March 2017, The Journal of infectious diseases,
Loveleen Bansi, and Caroline Sabin, and Richard Gilson, and Brian Gazzard, and Clifford Leen, and Jane Anderson, and David Dunn, and Teresa Hill, and Martin Fisher, and Jonathan Ainsworth, and Deenan Pillay, and Margaret Johnson, and John Walsh, and Chloe Orkin, and Philippa Easterbrook, and Mark Gompels, and Andrew Phillips, and
Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens.
May 2021, The Pediatric infectious disease journal,
Copied contents to your clipboard!